Pathogenic fungus

Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells

Retrieved on: 
Dienstag, Januar 9, 2024
Entrepreneurship, Senior, Family, Pathogenic fungus, Allergen, Farmer, Breeding, SAN, Food security, Nitrogen, Breakthrough, Fertilisation, Carbon, Regeneration, Research and development, Genome, CBUS, Plant, Disease resistance, Research, Gene editing, Agriculture

Breakthrough believed to represent the world’s first successful regeneration of a wheat plant from single cells – a major breakthrough for Cibus and for the seed industry.

Key Points: 
  • Breakthrough believed to represent the world’s first successful regeneration of a wheat plant from single cells – a major breakthrough for Cibus and for the seed industry.
  • Provides another single cell regeneration system to make Cibus’ High Throughput Breeding Process (the “Trait Machine™ System”) operational for a key cereal crop integral to food security globally.
  • Wheat breakthrough demonstrates the Company’s continued success in developing scalable high throughput breeding platforms that can operate as extensions of seed company breeding programs.
  • This is a major breakthrough for Cibus as well as for the industry.

Global Antifungal Agents Market Report 2022: Rising Incidences of Fungal Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Oktober 20, 2022
Health, Other Health, MSD, Skin infection, CDC, Pandion, Laboratory, Aspergillosis, Therapy, Growth, Abbott Laboratories, Antifungal, Pfizer, CAGR, Bayer, Patient, Fungus, Mycosis, Surgeon, Watchlist, Powder, Azole, World Health Organization, Infection, Partnership, WHO, Candidiasis, Center, World, Acquisition, Dermatophytosis, Africa Centres for Disease Control and Prevention, Joint Medical Service (Germany), Pathogenic fungus, Tinea versicolor, Bacteria, Death, Tablet, Canker, Polyene, Vaccine, Pharmaceutical industry, Merck, Echinocandin, Allylamine

The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.

Key Points: 
  • The global antifungal agents market is anticipated to grow at a significant CAGR of nearly 3.5% during the forecast period.
  • Antifungal agents prevent and destroy the growth of fungi that are responsible for several diseases such as aspergillosis, ringworm, and skin infection, among others.
  • Antifungal agents are a class of drugs that are used to detect and eliminate fungal infections from the body with minimal side effects.
  • Another major factor contributing to the growth of the market is the rising incidences of fungal diseases.

Global Antifungal Agents Market Report 2021-2027 Featuring Major Players - Abbott Laboratories, Pfizer, and Bayer - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Februar 3, 2022
Infectious Diseases, Pharmaceutical, Health, Growth, Risk, Patient, Partnership, Fungemia, Canker, Cell, Infection, Korea Disease Control and Prevention Agency, Pfizer, Abbott Laboratories, Aspergillosis, Subclinical infection, Mycosis, Candidiasis, Laboratory, Antifungal, Center, Bayer, COVID-19, Prevalence, CDC, Bloodstream infections, Drug discovery, Fungus, Medical tourism, Pathogenic fungus, Azole, Pharmaceutical industry, Echinocandin

The "Global Antifungal Agents Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antifungal Agents Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • This, in turn, is encouraging the demand for antifungal agents that can fight fungal infection without damaging cells of the body.
  • The global antifungal agents market is segmented based on drug class, dosage type, and route of administration.
  • Major players in the market include Abbott Laboratories, Inc., Pfizer Inc., and Bayer AG, among others.

UVC disinfection technology shown to inactivate Candida auris and Candida albicans

Retrieved on: 
Mittwoch, Juni 16, 2021
Yeasts, Branches of biology, Pathogenic microbes, Medical specialties, Organisms, Gut flora, Cándida, Pathogenic fungus

MEMPHIS, Tenn., June 16, 2021 /PRNewswire/ --The Tru-D UVC disinfection device has been shown to be effective against Candida auris and Candida albicans in both direct and indirect line of sight, according to a new study, "Inactivation of Candida auris and Candida albicans by ultraviolet-C," in Infection Control and Hospital Epidemiology (ICHE).

Key Points: 
  • MEMPHIS, Tenn., June 16, 2021 /PRNewswire/ --The Tru-D UVC disinfection device has been shown to be effective against Candida auris and Candida albicans in both direct and indirect line of sight, according to a new study, "Inactivation of Candida auris and Candida albicans by ultraviolet-C," in Infection Control and Hospital Epidemiology (ICHE).
  • The device delivers a measured dose of UVC energy from a single location in the room, eliminating lingering pathogens in the space.
  • Candida auris is an emerging fungal pathogen that is often resistant to antifungal drugs.
  • Adding Tru-D's enhanced UVC disinfection technology to existing hospital cleaning protocols has been shown to provide a cleaner hospital environment for patients.

Key Publication of Clinical Study Demonstrates Unyvero Lower Respiratory Tract (LRT) Panel is Likely to Alter Antibiotic Management of Significant Numbers of Patients Presenting with Suspected Pneumonia

Retrieved on: 
Mittwoch, September 2, 2020
Fungi, Infectious diseases, Ascomycota, Organisms, Medical specialties, HIV/AIDS, Pneumocystis pneumonia, Pneumocystis jirovecii, Pneumocystidomycetes, Pathogenic fungus, PJP, Pneumonia

Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.

Key Points: 
  • Antibiotics could have been optimized in 7.8% of patients through both de-escalation and expansion.
  • Unyvero LRT BAL is the only FDA-cleared lower respiratory tract infection panel that includes Pneumocystis jirovecii, a causative agent of Pneumocystis pneumonia (PJP) and a key fungal pathogen often found in immunocompromised patients that can be difficult to diagnose.
  • This press release includes statements regarding the potential impact on antibiotic therapy regimen and clinical utility of the Unyvero LRT and LRT BAL cartridges.
  • We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

Retrieved on: 
Mittwoch, Mai 20, 2020
Fungi, Organisms, Branches of biology, Antifungals, Echinocandins, Pathogenic fungus, Aspergillus, Cándida

Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.

Key Points: 
  • Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
  • With one drug, rezafungin, given once-weekly, we may be able to overcome these substantial limitations to improve patient outcomes in this highly immunosuppressed population.
  • Patients with compromised immune systems face complex drug regimens when undergoing BMT and experience a high mortality rate if infected.
  • The ReSPECT trial is a global, randomized, double-blind, controlled, pivotal Phase 3 trial of rezafungin versus the standard antimicrobial regimen to prevent invasive fungal disease due to Candida, Aspergillus and Pneumocystis in subjects undergoing allogeneic BMT.

SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference

Retrieved on: 
Donnerstag, März 5, 2020
Fungi, Organisms, Aspergillus, Aspergillosis, Azole, Terreus, Pathogenic fungus, RTT, Aspergillus fumigatus, Antiprotozoal agents, Antifungals, Chronic pulmonary aspergillosis

These in vitro data showed synergistic activity of ibrexafungerp in combination with azoles against Aspergillus isolates.

Key Points: 
  • These in vitro data showed synergistic activity of ibrexafungerp in combination with azoles against Aspergillus isolates.
  • The data presented here strengthens our conviction that ibrexafungerp, as part of a combination regimen with azole agents, could play a role in combating Aspergillus infections.
  • We are conducting multiple clinical trials evaluating ibrexafungerp for the treatment of invasive aspergillosis and other life-threatening fungal pathogens.
  • The effect of ibrexafungerp on improving azole susceptibility for azole-resistant strains of Aspergillus calidoustus and Aspergillus terreus was particularly noteworthy.

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

Retrieved on: 
Dienstag, September 24, 2019
Fungi, Holomycota, Immunodeficiency, Aspergillus, Pathogenic fungus

Presenter: Nathan P. Wiederhold, PharmD., Professor, University of Texas Health San Antonio, San Antonio, TX

Key Points: 
  • Presenter: Nathan P. Wiederhold, PharmD., Professor, University of Texas Health San Antonio, San Antonio, TX
    Full abstracts can be accessed through the IDWeek website.
  • Manogepix (APX001A), the active moiety of fosmanogepix (APX001), inhibits the highly conserved fungal enzyme Gwt1, compromising growth of fungal pathogens.
  • In multiple nonclinical studies, manogepix has shown broad-spectrum activity against common species ofCandida andAspergillus, including multi-drug resistant strains, such asC.
  • Amplyx Pharmaceuticals is focused on developing innovative therapies for patients with compromised immune systems, including cancer and transplant patients, and the critically ill.

Hedging Their Bets: Worcester Polytechnic Institute Study Reveals the Intertwined Response of Pathogen and Host During Fungal Infections

Retrieved on: 
Mittwoch, September 18, 2019
Medical specialties, Animal diseases, Infectious diseases, RTT, Yeasts, Gut flora, Pathogenic microbes, Vagina, Candidiasis, Vaginitis, Pathogenic fungus, Cándida

This never before observed coordination may point the way to new tools for studying fungal diseases and provide new clues into how to treat fungal infections, including sometimes deadly systemic infections.

Key Points: 
  • This never before observed coordination may point the way to new tools for studying fungal diseases and provide new clues into how to treat fungal infections, including sometimes deadly systemic infections.
  • Fungal diseases, particularly those caused by Candida, a genus prevalent in humans that is responsible for oral thrush, ear infections, and vaginitis, are notoriously difficult to treat.
  • In fact, both host and pathogen seem to engage in this strategy, the authors noted in the Nature Communications paper.
  • She said that a better understanding of the intertwined fates of macrophages and C. albicans could help identify new strategies for treating fungal infections.

World's frogs under assault by lone pathogenic killer, FIU scientist says

Retrieved on: 
Freitag, März 29, 2019
Fungi, Holomycota, Branches of biology, Chytridiomycota, Biodiversity, Infection, Pathogenic fungus

Aside from the 90 species reportedly extinct, Catenazzi said 40 percent of the other impacted species continue to experience population declines.

Key Points: 
  • Aside from the 90 species reportedly extinct, Catenazzi said 40 percent of the other impacted species continue to experience population declines.
  • "We don't have any other example of infectious disease causing biodiversity loss at any comparable scale," he said.
  • The chytrid fungus also produces toxins that paralyze white blood cells, thus impairing immune response of infected amphibians.
  • He has long known that fungal diseases are increasingly threatening animals and plants something he has witnessed up-close in his work.